Careers  |  Sign In  |  Register  |   Twitter

Vaccine Finds Success Combatting Most Fatal Brain Cancer

Recent trials from Celldex Therapeutics Inc have demonstrated the potential of their new vaccine, Rintega, in treating patients with glioblastoma multiforme (GBM) by utilizing the immune system in conjunction with other drugs, reports Reuters. Of the 73 patients with the recurrent malignant tumor, thirty percent of patients treated with Rintega and Roche‘s drug, Avastin, survived at least a year and a half compared to the fifteen percent on Avastin alone. The average survival rate of patients with this brain cancer is only 14-15 months even with chemotherapy. With no cure and nearly 9,000 new patients each year, the drug is being considered for expedited approval according to the FDA.


Read the article published by Reuters.